[Treatment of @entity1 with XXXX and esophageal varices].

@entity1 @entity157 @entity99 @entity1416
Fifty-nine @entity1 with @entity157 associated with advanced esophageal varices who received a variety of therapeutic modalities in the past 10 years at our department were reviewed. Our therapeutic modalities are hepatic resection, @entity99 ( @entity99 ) and @entity1416 ( @entity1416 ) for those with @entity157 and non-shunting treatment (NST; esophageal transection or Hassab's procedure) and endoscopic sclerotherapy (ST) for those with esophageal varices. A @entity1 selection was made by our own criterial developed by a multiple regression analysis for the @entity157 and KICG value for esophageal varices. Out of 59.16 underwent hepatic resection and NST. Eight survived more than 2 years. The longest survivor has been living for 4 yr and 4 months. Two-year survival rate is 69.8%. Another 16 underwent @entity99 and NST. Two-year survival was 14.6%. Another 7 underwent ST following hepatic resection or @entity99 . Five of the 7 received an emergency ST. Hemostasis was achieved in all of them. Two-year survival was 21.8%. The remaining 20 underwent ST and @entity1416 ; 13 received an emergency ST with 85% of hemostasis rate. None of them survived more than 2 years. From these data, it is suggested that a proper selection of @entity1 for a proper therapeutic modality improves the prognosis even in those with @entity157 associated with advanced esophageal varices.
